

NOTICE TO BONDHOLDERS

Notice to the holders of Marinomed Biotech AG (the "**Company**")
4.00% Bonds 2017-2021 with Conditional Conversion Rights, ISIN Code: AT0000A1WD52 (the "**Bonds**"), admitted to trading on the Third Market (*Dritter Markt*) of the Vienna Stock Exchange (*Wiener Börse*) (the "**Bondholders**").


We hereby inform the Bondholders that the Company's share capital has been increased from EUR 132,360 by EUR 867,640 to EUR 1,000.000 through issuance of 867,640 new shares against payment of a subscription price of EUR 1.00 for each new share. The capital increase has been registered with the commercial register on 15 October 2018.

In accordance with § 10 para (2) of the terms and conditions of the Bonds (the "**Terms and Conditions**"), the Conversion Price I (as defined in the Term and Conditions) has therefore been adjusted from EUR 302.2061 to EUR 40.8676.

Terms not otherwise defined herein have the same meaning as given in the Terms and Conditions.

Vienna, this 15 October 2018

Marinomed Biotech AG



DI Dr. Andreas Grassauer

Managing Director



Dr. Eva Prieschl-Grassauer

Managing Director